期刊文献+

克拉霉素缓释包衣微丸的制备及体外释放度研究 被引量:5

Preparation and in Vitro Release Study of Sustained-release Coated Pellets Containing Clarithromycin
原文传递
导出
摘要 目的制备克拉霉素缓释包衣微丸,并对其体外释放度进行考察。方法采用挤出滚圆技术制备克拉霉素含药微丸。以优化的丙烯酸树脂类Eudragit NE30D和Eudragit L30D-55混和水分散体为包衣材料,采用流化床包衣技术,制备缓释包衣微丸。考察自制缓释微丸的体外释药速率,并与市售的克拉霉素缓释胶囊进行比较。结果通过释药行为的评价,得到优化的包衣处方为5∶1的Eudragit NE30D和Eudragit L30D-55混和包衣材料,其体外释放行为在不同的pH溶出介质中与市售制剂产品没有明显差异,体外释药过程符合一级释放模型。结论采用挤出滚圆和流化床技术,以及优化的Eudragit NE30D和Eudragit L30D-55混和水分散体包衣材料,成功制备了克拉霉素缓释包衣微丸。 OBJECTIVE To prepare sustained-release coated pellet containing clarithromycin, and to investigate its in vitro drug release behavior. METHODS Extrusion-spheronization technology was used to prepare clarithromycin-containing pellets. The drug contained pellets were coated with the optimized polymeric combination of Eudragit NE30D and Eudragit L30D-55 by using fluid-bed technology. In vitro drug release behavior of the coated pellets was studied and compared with the commercially available sustained-release capsules of clarithromycin. RESULTS There were no significant differences in different pH dissolution medium between the coated pellets and commercial products in drug release behavior, with optimized coating material as Eudragit NE30D and Eudragit L30D-55 at ratio of 5 : 1. The drug release mechanism of coated pellets was in accordance with first-order release model. CONCLUSIONS With extrusionspheronization and fluid-bed technology, the sustained-release coated pellets containing clarithromycin are successfully prepared by using the mixture aqueous dispersion of Eudragit NE30D and Eudragit L30D-55 as coating material.
出处 《中国现代应用药学》 CAS CSCD 2013年第2期143-147,共5页 Chinese Journal of Modern Applied Pharmacy
基金 广东省创新药物制剂工程技术研究开发中心(2011B080100019)
关键词 克拉霉素 挤出滚圆 流化床 丙烯酸树脂 缓释包衣微丸 clarithromycin extrusion-spheronization fluid-bed Eudragit sustained-release coated pellets
  • 相关文献

参考文献4

二级参考文献49

共引文献19

同被引文献44

  • 1王慧颖,邹梅娟,韩锐,程刚.盐酸普罗帕酮骨架型缓释微丸的制备及其释药机制的探讨[J].中国药剂学杂志(网络版),2011(1):7-15. 被引量:6
  • 2邢静娴,刘燕鹏,柳晓蕊,江桂生,吴传斌.挤出滚圆法制备克拉霉素微丸及工艺优化[J].中国现代应用药学,2011,28(S1):1334-1337. 被引量:4
  • 3国家药典委员会冲华人民共和国药典:二部[S].2010年版.北京:中国医药科技出版社,2010:附录ⅥH、附录IR.
  • 4中华人民共和国药典委员会.中国药典[S].2010版.北京:化学工业出版社,2010:316-318.
  • 5U.S. Deparment of Health and Human Services, FDA, Cen- ter for Drug Evaluation and Reserch.Guidance for indus- try: supae-mr: modified release solid oral dosage Jorms [EB/OL]. (1997-09) [2013-09-10]. http://www.fda.gov/ downloads/Drugs/Guidances/UCM070640.pdf.
  • 6Brattstrom C,Wilczek H, Tyden G. Hypertriglyceridemia in re- nal transplant recipients treated with sirolimus[J]. Transplant Proc, 1998,30: 3950-3951.
  • 7Hu X, Lin C, Chen D, et al. Sirolimus solid self-microemulsify- ing pellets: Formulation development, characterization and bio- availability evaluation[J]. Int J Pharmt, 2012,438 ( 1-2 ) : 123- 133.
  • 8HIGUCHI T. Mechanism of sustained-action medication, theoretical analysis of rate of release of solid drugs dispersed in solid matrices [J]. J Pharm Sci, 1963(52): 115.
  • 9Chwieduk CM, Curran MP. Pramipexole extended release[J], CNS Drugs,2010,24(4)-.327.
  • 10周桂荣,李云立,刘福利,陈玉洁,梁亚莉.盐酸曲马多包衣缓释片的制备及体外释药行为[J].沈阳药科大学学报,2008,25(5):352-355. 被引量:4

引证文献5

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部